Literature DB >> 20346068

Histopathology and immunophenotype of the spleen during acute antibody-mediated rejection.

B Kaplan1, T Jie, R Diana, J Renz, A Whinery, N Stubbs, E Bracamonte, C Spier, P Schubart, H Rilo, R Gruessner.   

Abstract

Splenectomy has been reported to have a beneficial effect in treating Acute antibody-mediated rejection (ABMR). This reason for this often rapid and profound beneficial effect is not readily apparent from what is known about normal splenic immunoarchitecture. While the spleen is rich in mature B cells, it has not been noted to be a repository for direct antibody-secreting cells. We present a case of a Native American female who received a renal transplant and developed a severe episode of ABMR. The patient was initially refractory to both plasmapheresis and IVIG. The patient underwent an emergent splenectomy with almost immediate improvement in her renal function and a rapid drop in her DR51 antibodies. Immunohistochemical stains of the spleen demonstrated abundant clusters of CD138+ plasma cells (>10% CD138 cells as opposed to 1% CD138 cells as seen in traumatic controls). Though this is a single case, these findings offer a rationale for the rapid ameliorative effect of splenectomy in cases of antibody rejection. It is possible that the spleen during times of excessive antigenic stress may rapidly turn over B cells to active antibody-secreting cells or serve as a reservoir for these cells produced at other sites.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20346068     DOI: 10.1111/j.1600-6143.2010.03067.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  7 in total

1.  Spleen-specific isoforms of Pax5 and Ataxin-7 as potential proteomic markers of lymphoma-affected spleen.

Authors:  Brij Bharti; Rajnikant Mishra
Journal:  Mol Cell Biochem       Date:  2015-01-09       Impact factor: 3.396

2.  Acute Antibody-Mediated Rejection in Renal Transplantation: Current Clinical Management.

Authors:  Carrie Schinstock; Mark D Stegall
Journal:  Curr Transplant Rep       Date:  2014-03-13

3.  Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma: Southwest Oncology Group Study S0350.

Authors:  Daruka Mahadevan; Joseph M Unger; Catherine M Spier; Daniel O Persky; Fay Young; Michael LeBlanc; Richard I Fisher; Thomas P Miller
Journal:  Cancer       Date:  2012-07-25       Impact factor: 6.860

Review 4.  Rational clinical trial design for antibody mediated renal allograft injury.

Authors:  Shaifali Sandal; Martin S Zand
Journal:  Front Biosci (Landmark Ed)       Date:  2015-01-01

5.  Antibody-mediated rejection: pathogenesis, prevention, treatment, and outcomes.

Authors:  Olivia R Blume; Sarah E Yost; Bruce Kaplan
Journal:  J Transplant       Date:  2012-03-24

6.  Laparoscopic splenectomy to salvage renal transplants from severe acute antibody-mediated rejection.

Authors:  Michael Latzko; Sakshi Jasra; Sana Akbar; Harry Sun; Sadanand Palekar
Journal:  Case Rep Transplant       Date:  2012-12-18

7.  Case Report: Splenic Irradiation for the Treatment of Chronic Active Antibody-Mediated Rejection in Kidney Allograft Recipients With De Novo Donor-Specific Antibodies.

Authors:  Lan Zhu; Zhiliang Guo; Rula Sa; Hui Guo; Junhua Li; Gang Chen
Journal:  Front Immunol       Date:  2021-04-15       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.